117 related articles for article (PubMed ID: 7821846)
1. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer.
Buller RE; Niemann T; Connor JP; Squatrito RC; Skilling JS; Anderson B
Gynecol Oncol; 1995 Jan; 56(1):39-44. PubMed ID: 7821846
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
3. Characterization and development of UCI 107, a primary human ovarian carcinoma cell line.
Gamboa G; Carpenter PM; Podnos YD; Dorion G; Iravani L; Bolton D; Mascarello JT; Manetta A
Gynecol Oncol; 1995 Sep; 58(3):336-43. PubMed ID: 7672698
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a human ovarian carcinoma cell line: UCI 101.
Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
[TBL] [Abstract][Full Text] [Related]
5. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
6. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
8. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
10. Familial ovarian cancer.
Buller RE; Anderson B; Connor JP; Robinson R
Gynecol Oncol; 1993 Nov; 51(2):160-6. PubMed ID: 7903948
[TBL] [Abstract][Full Text] [Related]
11. Immunologic characterization of tumor markers in human ovarian cancer cell lines.
Kutteh WH; Miller DS; Mathis JM
J Soc Gynecol Investig; 1996; 3(4):216-22. PubMed ID: 8796833
[TBL] [Abstract][Full Text] [Related]
12. Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case.
Kaplan EJ; Caputo TA; Shen PU; Sassoon RI; Soslow RA
Gynecol Oncol; 1998 Aug; 70(2):289-94. PubMed ID: 9740708
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
14. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
16. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Jones J; Lagasse LD; Karlan BY
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
[TBL] [Abstract][Full Text] [Related]
17. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
18. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
